NCT02187445View on ClinicalTrials.gov

Inhaled Corticosteroid Use to Prevent Acute Chest Syndrome Recurrence in Children Between 1 and 4 With Sickle Cell Disease: a Feasibility Trial

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

December 31, 2016

Study Completion Date

February 13, 2017

Conditions
Sickle Cell DiseaseAsthmaAcute Chest Syndrome
Interventions
DRUG

Budesonide inhalation suspension

To determine the acceptability of budesonide inhalation suspension (BIS) 0.5 QD for 6 months for children with SCD that develop ACS between 1 and 4 years of age (n=10).

Trial Locations (1)

37232-9000

Vanderbilt University Medical Center, Nashville

Sponsors
All Listed Sponsors
collaborator

Emory University

OTHER

collaborator

Children's National Research Institute

OTHER

lead

Vanderbilt University

OTHER